Share on StockTwits

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) Director Seamus Mulligan sold 50,000 shares of the company’s stock in a transaction dated Wednesday, June 25th. The shares were sold at an average price of $149.69, for a total transaction of $7,484,500.00. Following the completion of the sale, the director now directly owns 1,405,555 shares in the company, valued at approximately $210,397,528. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Shares of Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) traded down 0.45% during mid-day trading on Thursday, hitting $149.74. 401,322 shares of the company’s stock traded hands. Jazz Pharmaceuticals plc – has a one year low of $67.62 and a one year high of $176.60. The stock has a 50-day moving average of $140.1 and a 200-day moving average of $141.5. The company has a market cap of $8.893 billion and a price-to-earnings ratio of 114.39.

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) last released its earnings data on Thursday, May 8th. The company reported $1.61 EPS for the quarter, missing the Thomson Reuters consensus estimate of $1.79 by $0.18. The company had revenue of $247.00 million for the quarter, compared to the consensus estimate of $254.86 million. During the same quarter in the prior year, the company posted $1.37 earnings per share. The company’s quarterly revenue was up 25.8% on a year-over-year basis. Analysts expect that Jazz Pharmaceuticals plc – will post $8.07 EPS for the current fiscal year.

A number of analysts have recently weighed in on JAZZ shares. Analysts at Zacks reiterated a “neutral” rating on shares of Jazz Pharmaceuticals plc – in a research note on Friday, June 20th. They now have a $157.00 price target on the stock. Separately, analysts at JMP Securities initiated coverage on shares of Jazz Pharmaceuticals plc – in a research note on Tuesday, June 17th. They set an “outperform” rating and a $179.00 price target on the stock. Finally, analysts at Wells Fargo & Co. initiated coverage on shares of Jazz Pharmaceuticals plc – in a research note on Tuesday, June 10th. They set an “outperform” rating on the stock. Five research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $171.50.

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.